Alpha-1 Antitrypsin Deficiency Management

Introduction to Alpha-1 Antitrypsin Deficiency

Low alpha-1 antitrypsin (AAT) protein levels indicate alpha-1 antitrypsin deficiency, a hereditary condition that significantly increases risk for developing pulmonary emphysema and liver disease, requiring targeted testing in at-risk populations and consideration of augmentation therapy for those with clinically evident emphysema, as recommended by the American Thoracic Society 1, 2
Alpha-1 antitrypsin is a 52-kD single-chain glycoprotein that functions primarily as a protease inhibitor, with its major biological role being inhibition of neutrophil elastase (NE), an enzyme that degrades elastin and other components of lung tissue, according to the American College of Chest Physicians 1

Pulmonary emphysema of the panacinar type is the most prevalent clinical consequence of AAT deficiency and is the major cause of disability and death, as stated by the American Thoracic Society 1
Symptomatic obstructive lung disease typically presents between ages 32 and 41 in individuals with a history of smoking, as reported by the American College of Chest Physicians 3
Liver disease is the second most frequent clinical complication, and may present in infancy as cholestasis, which usually resolves by adolescence, according to the American Association for the Study of Liver Diseases 1

Testing for AAT deficiency should be considered in individuals with early-onset emphysema (regardless of smoking history), all subjects with COPD, adults with bronchiectasis without evident etiology, patients with asthma whose spirometry fails to normalize with therapy, liver disease of unknown cause, and family members of known AAT-deficient patients, as recommended by the American College of Chest Physicians 3
Diagnostic testing involves measuring serum or plasma AAT levels (primary screening test), and in moderate clinical suspicion cases, an AAT level ≥ 23 mmol/L (≥ 1.2 g/L) rules out severe AAT deficiency, according to the American Thoracic Society 2, 4

Early diagnosis is crucial as late diagnosis has been associated with reduced functional status, quality of life, and worse overall survival, as stated by the American College of Chest Physicians 2
Management approaches include smoking cessation and avoidance of environmental irritants, maintaining up-to-date vaccination status, exercise, healthy diet, and pulmonary hygiene, as recommended by the American Thoracic Society 2

Without treatment, AAT deficiency can lead to premature disability and death, with 72% of deaths due to emphysema, as reported by the American College of Chest Physicians 3
Long-term surveillance for early detection of lung and liver diseases is recommended, and family screening should be encouraged to identify relatives who may be affected, as stated by the American Thoracic Society 2

The American Thoracic Society/European Respiratory Society recommends explicit screening (Type A recommendation - the strongest) for all first-degree relatives of individuals with alpha-1-antitrypsin deficiency, even in the absence of pulmonary symptoms 5, 6
First-degree relatives (brothers, sisters, children, parents) of an individual with confirmed alpha-1-antitrypsin deficiency should be tested because they have a significantly increased risk of being homozygous (PIZZ) or heterozygous (PIMZ, PI*SZ) 5, 6

The Canadian Thoracic Society's 2025 guidelines confirm that individuals with a first-degree relative with documented deficiency should be tested 7
Early identification allows for the implementation of crucial preventive measures, including absolute avoidance of smoking, which is the most important modifiable risk factor 8
In individuals deficient in alpha-1-antitrypsin who never smoke, life expectancy can be nearly normal (69 years for non-smokers versus 49 years for smokers in the Danish cohort) 8

Even heterozygotes (PI*MZ) may have an increased risk of lung disease, particularly if they smoke or have occupational exposures 9
Early detection enables avoidance of risky occupational exposures (dust, fumes, respiratory irritants) 8

Measurement of serum alpha-1-antitrypsin level as the initial screening test 7
If the level is ≥ 23 mmol/L (≥ 1.2 g/L), this excludes severe deficiency 7
If the level is low (< 11 mmol/L or < 0.57 g/L), this indicates severe deficiency requiring confirmation 7
Genotyping or phenotyping to identify the specific genotype (PIZZ, PIMZ, PI*SZ, etc.) 5, 7, 6

Before testing, discuss potential implications including risks of genetic discrimination (insurance, employment) and psychological burden 5, 6
However, the benefits of early detection (modification of risk behaviors, appropriate surveillance) generally outweigh these risks 5, 9
This screening recommendation does not apply to general population screening of asymptomatic individuals without risk factors 10, 11
The USPSTF guidelines recommend against spirometric screening for COPD in asymptomatic adults without a family history of alpha-1-antitrypsin deficiency 10, 11